PTA-News: Biofrontera AG: Biofrontera establishes UK subsidiary to strengthen its sales activities in the country

Thursday, 08. December 2022 13:55

Business news for the stock market

Leverkusen, Germany (pta008/08.12.2022/13:55) - Biofrontera AG (FSE: B8F), an international biopharmaceutical company, announces that it has established a subsidiary to continue the commercialisation of Ameluz® in the United Kingdom.

The newly founded Biofrontera UK Ltd. Is based in Cambridge, UK and headed by Ms. Pilar de la Huerta and Dr. Montserrat Foguet as Managing Directors. The company will take over the marketing activities for Ameluz® and the red-light lamp BF-RhodoLED® in Great Britain.

"The incorporation emphasizes our long-term strategic interest in the British pharmaceutical market and also its important role in Europe. We want to significantly expand our sales efforts in the UK in the future and are now setting the basis for this," commented Ms. de la Huerta, CFO of Biofrontera AG.

-END-

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (Prime Standard). www.biofrontera.com

Forward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "will," "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, including, but not limited to, the risk that the termination of the ADS Level 1 Program or the deregistration with the SEC may not occur or may be delayed, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate

[ source: https://www.pressetext.com/news/20221208008 ]

Related Links: Biofrontera AG
Author: